-
Azenta Life Sciences and Frontier Space Forge Alliance to Advance Research Infrastructure Beyond Earth
NASDAQ: $AZTA A New Frontier for Life Sciences: Azenta Partners with Frontier Space for Space-Based Research Azenta, Inc., a global leader in life sciences solutions, has announced a significant strategic partnership with Frontier Space, a pioneer in commercial space-based research systems. This collaboration marks a pivotal moment, uniting Azenta’s expertise in sample management with Frontier…
-
Eli Lilly Acquires Orna Therapeutics to Pioneer In Vivo Cell Engineering and Advance Next-Generation Therapies
NYSE: $LLY Eli Lilly and Company has announced a significant strategic move to bolster its capabilities in advanced therapeutics by entering into a definitive agreement to acquire Orna Therapeutics, Inc. This acquisition focuses on integrating Orna’s innovative platform for engineering immune cells directly within the body, aiming to revolutionize the treatment landscape for various diseases,…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-08-2026 TO 02-14-2026
Well well, The Seattle Seahawks take the Win in Super Bowl LX. This is what Google’s Gemini summarized regarding stock market prediction after the Win. And now, back to the BIO-TECH STOCK CATALYST REPORT. We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new…
-
Illumina Announces Fourth Quarter and Fiscal Year 2025 Financial Performance
NASDAQ: $ILMN Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company reported solid performance across its core sequencing segments, reflecting continued momentum in both clinical adoption and research applications globally. Fourth Quarter Financial…
-
Atossa Therapeutics Reinforces Z-Endoxifen’s Value Following Priority Review Voucher Program Reauthorization
NASDAQ: $ATOS Atossa Therapeutics, Inc. has underscored the continued strategic significance of its lead drug candidate, Z-Endoxifen, for the treatment of Duchenne Muscular Dystrophy (DMD). This reinforcement comes directly on the heels of recent legislative action by the U.S. Congress to reauthorize the Priority Review Voucher (PRV) program. Z-Endoxifen and the Importance of the PRV…
-
TransCode Therapeutics and Quantum Leap Advance TTX-MC138 Development with IND Amendment Submission for Phase 2a Trial
NASDAQ: $RNAZ A Significant Step Forward in Oncology Treatment TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative (QLHC) have jointly announced a noteworthy progression in their ongoing research and development efforts. The companies have officially submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA). This submission pertains to the…
-
PTC Therapeutics Announces Date for Fourth Quarter and Full-Year 2025 Financial Results
NASDAQ: $PTCT PTC Therapeutics, a biotechnology company focused on developing innovative treatments for rare diseases, has officially announced the date for the release of its financial performance data for the fourth quarter and the entirety of the 2025 fiscal year. Investors, analysts, and stakeholders can anticipate the official announcement on Thursday, February 19, 2026. This…
-
Insmed to Present Fourth Quarter and Full Year 2025 Financial Results
NASDAQ: $INSM Insmed Incorporated has officially announced the schedule for its upcoming financial results presentation. The company will host a conference call to discuss its financial performance for the fourth quarter and the entirety of the fiscal year 2025. This event is set to take place on Thursday, February 19, 2026. The conference call is…
-
Viking Therapeutics Announces Q4 and Full-Year 2025 Financial Results Date
NASDAQ: $VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released…
-
Decoy Therapeutics Highlights Global Access Commitment Following Investor Presentation
NASDAQ: $DCOY Decoy Therapeutics Showcases Commitment to Global Accessibility During Recent Investor Event Decoy Therapeutics, Inc. recently participated in a dedicated segment during a virtual investor conference, focusing a significant portion of its presentation on the implications and execution strategy of its recently announced Global Access Commitment Agreement. The company utilized this platform to elaborate…